{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:50:44Z","timestamp":1761126644372},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s10165-011-0585-6","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T12:20:01Z","timestamp":1326716401000},"page":"791-795","source":"Crossref","is-referenced-by-count":4,"title":["Good response to infliximab in a patient with deep vein thrombosis associated with Beh\u00e7et disease"],"prefix":"10.1093","volume":"22","author":[{"given":"Shuzo","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Hanafusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,13]]},"reference":[{"key":"585_CR1","unstructured":"Criteria for diagnosis for Beh\u00e7et\u2019s disease. International Study Group for Beh\u00e7et\u2019s Disease. Lancet. 1990; 335:1078\u201380."},{"key":"585_CR2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"585_CR3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/BOR.0b013e32831de4e7","volume":"21","author":"G Tomasson","year":"2009","unstructured":"Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21:41\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"585_CR4","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, K\u00f6tter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, St\u00fcbiger N, Yurdakul S, Yazici H, EULAR Expert Committee. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis. 2008;67:1656\u201362.","journal-title":"Ann Rheum Dis"},{"key":"585_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease. Lancet. 2001;358:295\u20136.","journal-title":"Lancet"},{"key":"585_CR6","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"585_CR7","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, G\u00fcl A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum"},{"key":"585_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","volume":"272","author":"H Kikuchi","year":"2008","unstructured":"Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Beh\u00e7et\u2019s syndrome. J Neurol Sci. 2008;272:99\u2013105.","journal-title":"J Neurol Sci"},{"key":"585_CR9","first-page":"341","volume":"19","author":"JT Lie","year":"1992","unstructured":"Lie JT. Vascular involvement in Beh\u00e7et\u2019s disease: arterial and venous and vessels of all sizes. J Rheumatol. 1992;19:341\u20133.","journal-title":"J Rheumatol"},{"key":"585_CR10","first-page":"402","volume":"19","author":"Y Ko\u00e7","year":"1992","unstructured":"Ko\u00e7 Y, G\u00fcll\u00fc I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S, et al. Vascular involvement in Beh\u00e7et disease. J Rheumatol. 1992;19:402\u201310.","journal-title":"J Rheumatol"},{"key":"585_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366\u20139.","journal-title":"Ann Intern Med"},{"key":"585_CR12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/02841869409121767","volume":"33","author":"P Boffetta","year":"1994","unstructured":"Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol. 1994;33:591\u20138.","journal-title":"Acta Oncol"},{"key":"585_CR13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-126-4-199702150-00005","volume":"126","author":"A Masala","year":"1997","unstructured":"Masala A, Faedda R, Alagna S, Satta A, Chiarelli G, Rovasio PP, Ivaldi R, Taras MS, Lai E, Bartoli E. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med. 1997;126:292\u20135.","journal-title":"Ann Intern Med"},{"key":"585_CR14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","volume":"48","author":"S Iwata","year":"2009","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet\u2019s disease. Rheumatology (Oxford). 2009;48:1012\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"585_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H. Anti-TNF therapy in the management of Behcet\u2019s disease\u2014review and basis for recommendations. Rheumatology (Oxford). 2007;46:736\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"585_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","volume":"29","author":"SW Lee","year":"2010","unstructured":"Lee SW, Lee SY, Kim KN, Jung JK, Chung WT. Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report. Clin Rheumatol. 2010;29:91\u20133.","journal-title":"Clin Rheumatol"},{"key":"585_CR17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","volume":"65","author":"K Baki","year":"2006","unstructured":"Baki K, Villiger PM, Jenni D, Meyer T, Beer JH. Beh\u00e7et\u2019s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis. 2006;65:1531\u20132.","journal-title":"Ann Rheum Dis"},{"key":"585_CR18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s10067-006-0426-8","volume":"26","author":"LM Endo","year":"2007","unstructured":"Endo LM, Rowe SM, Romp RL, Buckmaster MA, Atkinson TP. Pulmonary aneurysms and intracardiac thrombi due to Beh\u00e7et\u2019s disease in an African-American adolescent with oculocutaneous albinism. Clin Rheumatol. 2007;26:1537\u20139.","journal-title":"Clin Rheumatol"},{"key":"585_CR19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","volume":"46","author":"E Seyahi","year":"2007","unstructured":"Seyahi E, Hamuryudan V, Hatemi G, Melikoglu M, Celik S, Fresko I, Yurdakul S, Yazici H. Infliximab in the treatment of hepatic vein thrombosis (Budd\u2013Chiari syndrome) in three patients with Behcet\u2019s syndrome. Rheumatology (Oxford). 2007;46:1213\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"585_CR20","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, Gul A, Bonqrand P, Roux H, Ocal L, Inan\u00e7 M, Capo C. Over production of monocyte derived tumor necrosis factor alpha, interleukin IL-6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544\u20139.","journal-title":"J Rheumatol"},{"key":"585_CR21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-4632.2009.03905.x","volume":"48","author":"SP Durmazlar","year":"2009","unstructured":"Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet\u2019s disease: high levels may indicate vascular involvement. Int J Dermatol. 2009;48:259\u201364.","journal-title":"Int J Dermatol"},{"key":"585_CR22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2230.2006.02157.x","volume":"31","author":"T Aki","year":"2006","unstructured":"Aki T, Karincaoglu Y, Seyhan M, Batcioglu K. Serum substance P and calcitonin gene-related peptide levels in Beh\u00e7et\u2019s disease and their association with disease activity. Clin Exp Dermatol. 2006;31:583\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"585_CR23","doi-asserted-by":"crossref","first-page":"e2011026","DOI":"10.4084\/mjhid.2011.026","volume":"3","author":"E Seyahi","year":"2011","unstructured":"Seyahi E, Yurdakul S. Beh\u00e7et\u2019s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3:e2011026.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"585_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-4632.2004.02184.x","volume":"44","author":"G Gur-Toy","year":"2005","unstructured":"Gur-Toy G, Lenk N, Yalcin B, Aksaray S, Alli N. Serum interleukin-8 as a serologic marker of activity in Beh\u00e7et disease. Int J Dermatol. 2005;44:657\u201360.","journal-title":"Int J Dermatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-011-0585-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:25:30Z","timestamp":1646843130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-011-0585-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,13]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1007\/s10165-011-0585-6","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,13]]}}}